Proof of Concept in Animals for AdaptVac’s breast cancer vaccine candidate published in scientific journal
Hørsholm, Denmark, 28 November 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”)’s 50% owned joint venture, AdaptVac’s, scientific paper presenting proof of concept in animals (POCA) for its novel breast cancer vaccine candidate, AV001, will be published in the peer reviewed scientific journal ‘OncoImmunology’. The results demonstrate that AV001 is effective for both prevention and therapy of breast cancer in an advanced mouse model.
“I am very pleased that the previously announced data demonstrating proof concept in animals for AdaptVac’s breast cancer vaccine candidate is now published in a renowned peer reviewed journal. These convincing data constitute an important step towards reaching a license or collaboration agreement with a strong partner for the project”, says Dr. Steen Klysner, CEO of ExpreS2ion Biotechnologies.
AdaptVac’s scientific paper "Virus-like particle display of HER2 induces potent anti-cancer responses" will be published online today. The data for the proof of concept in animals for AV001 is based upon targeting so-called HER2-positive breast cancer tumours. The tumours were generated in an advanced HER2 transgenic mouse model. HER2 (human epidermal growth factor receptor 2) is a specific gene that plays a significant role in the development of breast cancer.
In the POCA study the article is based upon, the vaccine is demonstrated to be effective for both prevention and therapy of HER2-positive breast cancer tumours. The effect compares very well with the leading monoclonal antibody therapy on the market today. In addition, the results indicate a potential for AV001 as a rescue therapy for non-responders or patients for whom the treatment with monoclonal antibodies fails due induce immune response.
AdaptVac’s press release, as well as the full article, when available, can be found at AdaptVac’s website: https://www.adaptvac.com/news
Strong market potential
Breast cancer affect more than 1.3 million worldwide annually, resulting in more than 450,000 deaths (Tao, 2015: www.ncbi.nlm.nih.gov/pubmed/25543329). The most common treatment today is based on monoclonal antibodies, where the dominating therapy HERCEPTIN (trastuzumab) generates annual global sales of US$ 7 billion. The target product profile of AdaptVac's lead breast cancer project is highly competitive to this in terms of cost and efficacy, thus aiming at a significant market share.
About AdaptVac ApS
AdaptVac is a joint venture between ExpreS2ion Biotechnologies and NextGen Vaccines, combining ExpreS2ion’s platform with novel proprietary and ground-breaking Virus-Like Particle (VLP) technology, developed at the University of Copenhagen. The company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders.
Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
This press release contains information that ExpreS2ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on November 28, 2017.
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion’s unique proprietary platform technology, ExpreS2, is designed to enable accelerated, cost effective development and robust production of complex proteins for new vaccines and diagnostics. Since founded in 2010, more than 250 proteins involved in e.g. malaria and Zika were produced in collaborations with research institutions and companies with a superior efficiency and success rate. ExpreS2ion also develops competitive virus-like-particle based vaccines through its joint venture AdaptVac, which was founded in 2017.